Reports Q3 revenue $3.71B, consensus $3.69B. “Baxter continues to successfully execute upon the slate of strategic actions we announced at the outset of 2023,” said Jose (Joe) E. Almeida, chairman, president and chief executive officer. “These initiatives are centered on enhancing business performance and increasing innovation, to drive incremental value for all of our stakeholders. This progress is demonstrated across several actions this quarter, including the completion of the BioPharma Solutions divestiture, verticalization of our four business segments and solid third-quarter performance. These milestones are critical in building momentum on Baxter’s ongoing transformation journey.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BAX:
- BAX Earnings this Week: How Will it Perform?
- Notable open interest changes for October 13th
- Dialysis stocks ‘over-reacting’ to FLOW top-line results, says Wells Fargo
- UBS Calls DaVita (NYSE:DVA) Sell-Off “Big Overreaction”
- Dialysis stocks slide after Novo stops kidney outcomes trial early for efficacy
